Navigation Links
Pressure BioSciences, Inc. to Present at the SeeThruEquity Spring Investor Microcap Forum
Date:3/11/2013

SOUTH EASTON, Mass., March 11, 2013 /PRNewswire/ -- Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company") today announced that Mr. Richard T. Schumacher , President and CEO, will present a corporate overview at SeeThruEquity's Spring Investor Microcap Forum on Tuesday, March 12th at 3:20 pm EDT.  The Investor Forum is being held at the Penn Club, 30 West 44th Street, New York, NY. Registration for the Investor Forum is available at www.seethruequity.com.

Mr. Schumacher's presentation will be webcast and may be viewed on the day of the presentation and up to 90 days thereafter on the Company's website (www.pressurebiosciences.com).

About SeeThruEquity LLC:SeeThruEquity, LLC is an investment research and corporate access firm that produces high quality research reports on small- and micro-cap companies with less than $1 billion in market capitalization. These companies are typically underserved by the traditional Wall Street analyst establishment. SeeThruEquity is unfettered by any ties to investment banking or trading, and distributes its high impact research as an approved firm for consensus estimates on Thomson Reuters, CapitalIQ, FactSet, Zacks and StockTwits, as well as to its own audience of investors from its corporate website.

SeeThruEquity's philosophy is focused on delivering an unbiased, institutional quality research product for uncovered or under covered companies to all levels of investors in the investment community and at absolutely no charge to the reader of the research or the company being covered. The firm seeks to build relationships between corporate issuers and institutional and sophisticated investors via compelling investor conferences and forums as well as non-deal road shows.

About Pressure BioSciences, Inc.Pressure BioSciences, Inc. ("PBI") (OTCQB: PBIO) is focused on the development, marketing, and sale of proprietary laboratory instrumentation and associated consumables based on Pressure Cycling Technology ("PCT"). PCT is a patented, enabling technology platform with multiple applications in the estimated $6 billion life sciences sample preparation market. PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions. PBI currently focuses its efforts on the development and sale of PCT-enhanced sample preparation systems (instruments and consumables) for mass spectrometry, biomarker discovery, bio-therapeutics characterization, vaccine development, soil and plant biology, forensics, histology, and counter-bioterror applications.

Forward Looking Statements Statements contained in this press release regarding PBI's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking'' statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2011, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

For more information about PBI and this press release, please click on the following website link:
http://www.pressurebiosciences.comInvestor Contacts: Richard T. Schumacher, President and CEO, PBI 

(508) 230-1828 (T)Conrad F. Mir, CFO, PBI

(508) 230-1828 (T)Timothy J. Connor, Managing Director, Benchmark Advisory

(858) 568-7059 (T)


'/>"/>
SOURCE Pressure BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Dr. Mickey Urdea Joins Pressure BioSciences Board of Directors
2. India Wound Care Management Market Outlook to 2018 - Advanced Wound Management, Wound Closure Devices, Pressure Relief Devices, Ostomy Drainage Bags and Others
3. BRICS NPWT Market and Pressure Relief Devices Industry Analysis in New Research Reports at ReportsnReports.com
4. Pressure Relief Devices Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018
5. North America Wound Care Management Market Outlook to 2018 - Advanced Wound Management, Wound Closure Devices, Pressure Relief Devices, Ostomy Drainage Bags and Other
6. In Preventing Diabetes-Related Heart Disease, Blood Pressure and Cholesterol Targets are Higher Priorities than Blood Sugar
7. Global Medical Device Marketing Groups Respond to Internal Cost Pressures
8. Flexpoint Completes Certification for Pressure Relief Device
9. Lower Copayments and Use of Mail-Order Pharmacy may Reduce Disparities in Adherence to Blood-Pressure Medication
10. Pressure BioSciences Announces Conversion of All Remaining Series E Convertible Preferred Stock by Ironridge BioPharma
11. Pressure BioSciences Partners with Constant Systems to Significantly Expand Product Offerings and International Distribution
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017 Research ... "Global Biosimilar Pipeline and Market Prospects: Addressing Production Complexities ... to their offering. ... "Global Biosimilar Pipeline and Market Prospects: Overcoming ... provides an in-depth assessment of the current trends in ...
(Date:4/20/2017)... April 20, 2017   ZappRx, Inc ., a digital ... prescribing process, today announced it closed $25 million in Series ... capital firm based in Seattle that ... Partners . The Series B round included participation from ... 2014, and GV (formerly Google Ventures). As part ...
(Date:4/20/2017)... Sweden , April 20, 2017 ... NEVPF) ("NeuroVive") today announced positive preclinical results ... preclinical compound for non-alcoholic steatohepatitis (NASH), in ... NV556 has previously shown ... NASH model. Today, NeuroVive,s scientists present novel ...
Breaking Medicine Technology:
(Date:4/26/2017)... St. Louis, Missouri (PRWEB) , ... April 26, ... ... optimal cost, quality and clinical outcomes, today released the podcast, “Make Plans ... Act in bringing value-based payment into the physician's office and how physicians and ...
(Date:4/26/2017)... N.J. (PRWEB) , ... April 26, 2017 , ... ... Inc. in Hackensack, N.J. has been honored by Enterprising Women magazine as ... that recognizes the world’s top women business owners. Winners have demonstrated that they ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... launched a unique website ( CRISPRCas.pioneer.com ) that demonstrates how this advanced plant ... produce more and better food, with fewer resources. It highlights the business’ principles, ...
(Date:4/25/2017)... ... April 25, 2017 , ... Splashtop Inc. , ... . This new addition to the Mirroring360 product family combines device screen mirroring ... Mirroring360 Pro enables educators, business professionals and individuals to stream or mirror app ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... attempts to compare student test score performance for the 2015-16 school year across ... state’s voucher programs. Though it highlights important patterns in student test score performance, ...
Breaking Medicine News(10 mins):